The NEDD9 (Neural precursor cell expressed, developmentally down-regulated 9) protein, also known as HEF1 or Cas-L, is a scaffolding adaptor protein belonging to the Cas (Crk-associated substrate) family. It plays critical roles in regulating cell adhesion, migration, and invasion by integrating signals from integrins, growth factor receptors, and other extracellular cues. Structurally, NEDD9 contains multiple protein interaction domains, including SH3-binding motifs and tyrosine phosphorylation sites, enabling its participation in pathways like FAK/Src, RAS-MAPK, and TGF-β signaling. Dysregulation of NEDD9 is linked to cancer progression, particularly in promoting metastasis in melanoma, breast, and lung cancers.
NEDD9 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies are commonly used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and immunoprecipitation (IP). High-quality NEDD9 antibodies specifically recognize epitopes within its N-terminal domain or C-terminal region, enabling detection of full-length proteins or phosphorylation-dependent activation states. Commercial NEDD9 antibodies are available in various host species (e.g., rabbit monoclonal, mouse polyclonal) and are validated for cross-reactivity in human, mouse, and rat samples. Research utilizing these antibodies has advanced understanding of NEDD9's role in EMT (epithelial-mesenchymal transition), cytoskeletal dynamics, and therapeutic resistance, making it a biomarker of interest in oncology and cell biology.